Chicago Partners Investment Group LLC Increases Holdings in Insulet Corporation $PODD

Chicago Partners Investment Group LLC increased its position in Insulet Corporation (NASDAQ:PODD) by 262.8% during the first quarter, HoldingsChannel.com reports. The fund owned 4,579 shares of the medical instruments supplier’s stock after acquiring an additional 3,317 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Insulet were worth $887,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Larson Financial Group LLC raised its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new stake in Insulet in the fourth quarter valued at $28,000. DV Equities LLC purchased a new position in shares of Insulet in the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. purchased a new position in shares of Insulet in the fourth quarter valued at $29,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PODD shares. Leerink Partners cut their price target on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Benchmark reissued a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. BTIG Research dropped their target price on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Bank of America cut their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, Raymond James Financial set a $216.00 price target on shares of Insulet in a report on Monday, June 8th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.25.

Insulet Trading Up 3.2%

Insulet stock opened at $164.43 on Friday. The stock has a 50-day moving average price of $152.81 and a 200 day moving average price of $207.20. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88. The stock has a market cap of $11.39 billion, a PE ratio of 38.24, a P/E/G ratio of 1.11 and a beta of 1.11. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the prior year, the firm earned $1.02 EPS. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts predict that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
• Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
• Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.